Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012: Phase I Study

NCT03784625 is registered in ClinicalTrials.gov with Centre Jean Perrin as lead sponsor.

NCT NCT03784625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03784625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012: Phase I Study
Lead sponsor
Centre Jean Perrin
Phase
Phase 1
Overall status
Completed
Start date
October 18, 2019
Completion date
January 17, 2025
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma